Antagonism of androgen and estrogen effects in guinea pig seminal vesicle epithelium and fibromuscular stroma by keoxifene (LY156758).
Using separated epithelium (SVE) and fibromuscular stroma (SVM) of guinea pig seminal vesicle, the antihormonal effects of daily subcutaneous administration (14 and 28 days) of the benzothiophene keoxifene (LY156758; [6-hydroxy-2-(4-hydroxyphenyl)benzo(b) thien-3-yl] [4-(2-1-piperidinyl) ethoxyl] phenyl) methanone hydrochloride) in intact, castrate, and androgen/estrogen-maintained castrate animals was evaluated. The compound was devoid of agonist activity in castrated males, in that the compound had no stimulatory effect on SVM wet weight or DNA content. In vitro cytosolic binding of [3H]estradiol (E2) in the SVM was decreased in a concentration-dependent manner by keoxifene, but the compound did not perturb the binding of [3H]dihydrotestosterone (DHT) in the SVM or SVE. Likewise, keoxifene administration to castrated males treated with exogenous steroids antagonized the estrogen-induced hyperplastic response of the SVM, whereas no interference with androgen-induced growth of the SVM or SVE was observed. Keoxifene treatment of intact male guinea pigs produced regression of the androgen-sensitive SVE as well as the androgen/estrogen-sensitive SVM. Keoxifene-induced decreases in guinea pig serum testosterone levels were associated with this activity. Histological analysis of the seminal vesicle under these conditions suggests androgen deprivation. These findings indicate that keoxifene is a physiological antagonist of androgen action in the intact male guinea pig. The pure estrogen antagonist properties of keoxifene and its ability to decrease accessory sex organ epithelium and fibromuscular stroma in vivo suggest potential applications of the benzothiophenes in the medical management of prostatic neoplasia.
Neubauer
B L
BL
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
Biser
P
P
Jones
C D
CD
Mariotti
A
A
Hoover
D M
DM
Thornton
T
T
Thornton
M O
MO
Goode
R L
RL
D000726:Androgen Antagonists / Q000494:pharmacology*; D000818:Animals; D003534:Cyproterone / Q000031:analogs & derivatives / Q000494:pharmacology; D017373:Cyproterone Acetate; D013196:Dihydrotestosterone / Q000378:metabolism; D004848:Epithelium / Q000187:drug effects; D004958:Estradiol / Q000378:metabolism; D004965:Estrogen Antagonists / Q000494:pharmacology*; D006168:Guinea Pigs; D008297:Male; D009132:Muscles / Q000033:anatomy & histology; D009919:Orchiectomy; D009929:Organ Size / Q000187:drug effects; D010880:Piperidines / Q000494:pharmacology*; D020849:Raloxifene Hydrochloride; D011944:Receptors, Androgen / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D012669:Seminal Vesicles / Q000033:anatomy & histology / Q000187:drug effects*
D000726:Androgen Antagonists; D004965:Estrogen Antagonists; D010880:Piperidines; D011944:Receptors, Androgen; D011960:Receptors, Estrogen; D013196:Dihydrotestosterone; D020849:Raloxifene Hydrochloride; D017373:Cyproterone Acetate; D004958:Estradiol; D003534:Cyproterone